PriceTargets.com logo

Cogent Biosciences - UMRX Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$6.53 As of 04/17/2024 01:00 AM ET
▲ +0.07 (1.08%)
Get New Cogent Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for UMRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for UMRX

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Cogent Biosciences in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $6.53.

This chart shows the closing price for UMRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Cogent Biosciences. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/25/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/23/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/23/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/22/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/20/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/18/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/18/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/17/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/2/2020Jefferies Financial GroupInitiated CoverageBuy$4.00High
7/7/2020WedbushUpgradeNeutral ➝ Outperform$1.00 ➝ $4.00High
3/29/2020WedbushReiterated RatingHold$1.00High
3/27/2020HC WainwrightLower TargetBuy$18.00 ➝ $4.00High
3/4/2020WedbushDowngradeOutperform ➝ NeutralHigh
3/3/2020Morgan StanleyDowngradeOverweight ➝ Equal WeightHigh
11/27/2019Morgan StanleyLower TargetOverweight$8.00 ➝ $3.00Medium
8/13/2019WedbushLower TargetOutperform$20.00 ➝ $13.00High
8/13/2019HC WainwrightReiterated RatingBuyHigh
8/12/2019CowenReiterated RatingHoldHigh
7/3/2019HC WainwrightSet TargetBuy$18.00Low
7/3/2019SunTrust BanksLower TargetHold ➝ Buy$6.00High
5/14/2019HC WainwrightReiterated RatingBuy$18.00Medium
(Data available from 4/18/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/21/2023
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2023
  • 2 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/20/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/19/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/18/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/19/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/18/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Cogent Biosciences logo
Cogent Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The firm's technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA.
Read More

Today's Range

Now: $6.53
Low: $6.39
High: $6.58

50 Day Range

MA: $10.50
Low: $2.35
High: $13.01

52 Week Range

Now: $6.53
Low: $0.29
High: $3.72

Volume

2,008,780 shs

Average Volume

1,222,692 shs

Market Capitalization

$277.32 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.93

Frequently Asked Questions

What sell-side analysts currently cover shares of Cogent Biosciences?

The following equities research analysts have issued reports on Cogent Biosciences in the last twelve months:
View the latest analyst ratings for UMRX.

What is the current price target for Cogent Biosciences?

0 Wall Street analysts have set twelve-month price targets for Cogent Biosciences in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Cogent Biosciences in the next year.
View the latest price targets for UMRX.

What is the current consensus analyst rating for Cogent Biosciences?

Cogent Biosciences currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for UMRX.

What other companies compete with Cogent Biosciences?

Other companies that are similar to Cogent Biosciences include Nektar Therapeutics, XBiotech, Pyxis Oncology, Verastem and Prelude Therapeutics. Learn More about companies similar to Cogent Biosciences.

How do I contact Cogent Biosciences' investor relations team?

Cogent Biosciences' physical mailing address is 200 CAMBRIDGE PARK DRIVE SUITE 3100, CAMBRIDGE MA, 02140. The company's listed phone number is (617) 945-5576 and its investor relations email address is [email protected]. The official website for Cogent Biosciences is www.unumrx.com. Learn More about contacing Cogent Biosciences investor relations.